Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDR
The experimentally established mechanism targets of Brivanib Alaninate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 5/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 16/20 | 0.75 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.75 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.75 |
| ▸ | FGFR4 known ✓ | P22455 | 1/20 | 0.75 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.75 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 2/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivanib Alaninate SCHEMBL13108648 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL483382 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL2263525 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL18319845 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29355920 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL29665039 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| Brivanib Alaninate SCHEMBL15971686 | 1.00 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13412331 | 0.95 | CYP3A4 (0.91) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3450304 | 0.93 | CYP3A4 (1.00) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8207945 | 0.91 | CYP3A4 (0.84) | CYP3A4FGFR1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110785187-B | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117203223-A | Lymphocyte targeting lentiviral vectors | 凯洛尼亚疗法有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117122707-A | combination therapy | 意大利国际先进加速器应用有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117015396-A | Compositions and methods for treating cancer with chimeric TIM receptors in combination with poly (ADP-ribose) polymerase inhibitors | 森罗治疗公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116390936-A | Chimeric TIM receptors and uses thereof | 森罗治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116059344-A | Antibodies that specifically bind to PD-1 and uses thereof | 詹森生物科技公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-114502590-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-108430515-B | Antibody conjugates comprising TOLL-like receptor agonists | 诺华股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-112867512-A | Combination therapy | 意大利国际先进加速器应用有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-107667092-B | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | 诺华股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112513085-A | PSMA binding agents and uses thereof | 詹森生物科技公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-112218886-A | Expression vector of chimeric phagocytic receptor, genetically modified host cell and application thereof | 森罗治疗公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-112218887-A | Cellular immunotherapy compositions and uses thereof | 森罗治疗公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-111386284-A | Chimeric phagocytic receptor molecules and methods of use | 森罗治疗公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111139256-A | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors | 诺华股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-105358576-B | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors | 诺华股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-110831967-A | IL-1 β binding antibodies for the treatment of cancer | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110785187-A | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2020-02-11 | — | — | CN | disclosed |